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University of Wisconsin solution has provided excellent myocardial pres. 
ervation. However, the high potassium content of the currently available 
University of Wisconsin solution has been implicated in coronary artery 
endothelial damage. We placed 16 neonatal (age 1 to 3 days) Duroc piglet 
hearts on an isolated nonworking perfusion circuit. Endothelium-depen- 
dent and endothelium-independent vasodilation were tested by measuring 
coronary blood flow after intracoronary infusion of bradykinin (10 -6 
mol/L) and nitroprusside (10 -6 mol/L), respectively. In addition, nitric 
oxide levels were measured after bradykinin i fusion. The hearts were then 
arrested blindly with either a modified University of Wisconsin solution 
(group 1; n = 8, K + = 25 mEq/L) or standard University of Wisconsin 
solution (group 2; n = 8, K + = 129 mEq/L) by infusion of cardioplegic 
solution every 20 minutes for a total of 2 hours. After bradykinin infusion, 
the mean coronary blood flow increased by 237.1% - 14.0% of baseline 
valves before arrest and by 232.8% +- 16.0% after arrest in group 1 (p = not 
significant). As in the first group, the mean coronary blood flow in group 2 
increased by 231.1% +_ 13.7% before arrest; however, the increase in mean 
coronary blood flow after arrest was significantly attenuated (163.3% +- 
12.8%, p < 0.01). The loss of endothelium-dependent coronary blood flow 
response in group 2 correlated with a decreased capacity to release nitric 
oxide after arrest (prearrest 8.25 +- 2.30 nmol/min per gram versus 
postarrest -2.46 - 2.29 nmol/min per gram, p < 0.01). Endothelium- 
independent vasodilatory response revealed no significant difference be- 
tween groups before and after arrest. These results suggest that the 
low-potassium University of Wisconsin solution provides superior protec  l 
tion of the endothelium by preserving the endothelium-dependent vasodi- 
latory response to nitric oxide release. (J Thorac Cardiovasc Surg 1996;112: 
103-10) 
T he University of Wisconsin solution (UWS), de- veloped by Wahlberg, Southard, and Belzer I in 
1986, has been used successfully to preserve the 
pancreas, 2 kidney, 3and liver 4 in both laboratory and 
clinical settings. Numerous studies have demon- 
strated that UWS also provides excellent myocardial 
preservation i  a variety of animal models. 5-s Fur- 
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thermore, clinical trials at various centers have 
proved that UWS is a safe and effective preservation 
solution for human cardiac transplantation. 9'1° 
These studies have demonstrated favorable effects 
of UWS on the myocyte but have not focused on its 
effects on either the conduction tissues or endothe- 
lium. Moreover, the optimum concentration and 
composition of its components have not been stan- 
dardized. The high potassium content (129 mmol/L) 
of UWS has been suspected of damaging the endo- 
thelium during preservation. 
Potassium is a recognized vascular irritant, and it 
has been shown to cause marked arterial endothelial 
damage] 1 Carpentier, Murawsky, and Carpentier 12 
have demonstrated the endothelial cytotoxicity of 
hyperkalemic rystalloid cardioplegic solutions to 
endothelial cells in tissue cultures. We recently 
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presented our clinical results that demonstrated 
twice the prevalence of accelerated graft atheroscle- 
rosis at 24 months after transplantation in the 
patient group that received UWS (21%, n = 100) 
compared with the Stanford solution group (10.5%, 
n = 100). Although UWS contributes significantly to 
successful myocardial functional recovery after stor- 
age, numerous laboratory studies have shown that 
UWS and other hyperkalemic cardioplegic solutions 
fail to preserve ndothelial functionJ 3-16 
The endothelium plays a significant role in vaso- 
regulation and coagulation homeostasis; it produces 
prostacyclin, plasminogen activator, antithrombin 
III, and endothelium-dependent relaxation factor 
(EDRF)j7, a8 EDRF, which has been demonstrated 
to be nitric oxide (NO), 19 has major effects on local 
vasoregulation by modulating vascular tone and 
inhibiting platelet aggregation and adhesion. 2°'21 
Endothelial damage during preservation exposes 
collagen fibers and the basement membrane and 
also induces the release of procoagulants. 22 There- 
fore disruption of the endothelium, and hence its 
normal physiologic functions, may have deleterious 
effects on myocardial perfusion, vascular permeabil- 
ity, endothelium-platelet in eractions, and, conse- 
quently, the long-term outcome after cardiac trans- 
plantations. 
We hypothesized that by decreasing the potas- 
sium content of the UWS we might improve pres- 
ervation of endothelial function. A previous tudy in 
our laboratory has shown that a modified low- 
potassium (25 mmol/L) UWS and the standard 
high-potassium UWS provide equivalent myocardial 
functional preservation. 23 The purpose of this study, 
therefore, was to examine and compare the effects 
of the potassium level on endothelial function by 
preserving hearts with either the standard high- 
potassium or the modified low-potassium UWS. 
Material and methods 
Experimental preparation. Hearts were harvested 
from 12 neonatal (1 to 3 days old) piglets (Duroc) without 
intervening ischemia nd placed on an isolated, nonwork- 
ing, blood-perfused circuit (Fig. 1). Adolescent Duroc pigs 
(50 to 70 kg), used as cross circulation support, were 
anesthetized with intramuscular ketamine (100 mg/kg) 
and acepromazine (0.1 mg/kg). Continuous intravenous 
pentobarbital diluted in 5% dextrose (5 mg/ml) and 
supplemented with boluses of pentobarbital through the 
femoral vein was administered for maintenance anesthe- 
sia. Mechanical ventilation (Bennet MA-1 ventilator, Pu- 
ritan-Bennet Corp., Los Angeles, Calif.) at an inspired 
oxygen fraction of 1.0, a positive end-expiratory pressure 
of 5 mm Hg, a tidal volume of 15 to 20 ml/kg, and a rate 
of 12 breaths/min was established. Arterial blood gas 
valves were obtained every 30 minutes (model ABL-330, 
Radiometer, Copenhagen, Denmark) and hematocrit val- 
ues every hour. The pH was maintained between 7.40 and 
7.50, carbon dioxide tension between 30 and 40 mm Hg, 
and oxygen tension higher than 400 mm Hg. Rectal 
temperature was maintained at 38 ° C by use of a heated 
water blanket (Medi-therm, model No. MTA-4700, Gay- 
mar Industries, Inc., Orchard Park, N.Y.). Systolic blood 
pressure was kept greater than 80 mm Hg by intravenous 
lactated Ringer's tandard solution or 6% hetastarch and 
the hematocrit level was kept greater than 25% by pro- 
viding intravenous blood obtained from a previous up- 
port pig. 
Blood from the support animal was directed through a 
roller pump (model 10-40-00, Stokert Instruments, Mu- 
nich, Germany), warmed to 38 ° C by a blood cardioplegia 
device (model BCD ADV-1, Shiley Inc., Irvine, Calif.), 
and delivered through the innominate artery to the aortic 
root of the harvested heart at a constant mean pressure of 
60 mm Hg. Perfusion and suspension of the heart were 
achieved by connection of the innominate artery cannula 
to the blood cardioplegia device while the distal aorta 
remained clamped. Concurrently, the aorta was cannu- 
lated with a 14-gauge perfusion cannula nd connected to 
an open adjustable column to control the coronary perfu- 
sion pressure. Silicone rubber tubing (1/4-inch outer diam- 
eter) was inserted into the pulmonary artery to collect 
coronary sinus effluent and measure coronary blood flow 
(CBF). Blood from the aortic column and pulmonary 
artery was returned to the support animal directed 
through a 40 /xm blood filter (Ultipor EC3840, Pall 
BioMedical Products Corp., East Hills, N.Y.). 
Pressure monitoring. Fiberoptic transducer-tipped 
catheter (1.3 mm outer diameter, model 110-4, Camino 
Laboratories, San Diego, Calif.) was advanced into the 
left ventricle via the left atrium for pressure monitoring. 
Aortic root pressure was simultaneously recorded with a 
fluid-filled transducer (Statham P23, Spectramed Inc., 
Oxnard, Calif.). 
Endothelial function test. After stabilization of base- 
line CBF (30 to 60 minutes after perfusion), endothelium- 
dependent vasodilation was tested by administration of 
bradykinin mixed in arterial blood to a final concentration 
of 10 -6 mol/L for 1 minute at a constant mean pressure of 
60 mm Hg. Immediately after the infusion, three separate 
minute volumes of coronary effluent were collected in 
graduated cylinders, and the average CBF was calculated 
and expressed as a percent increase in baseline CBF. In 
addition, 5 ml samples of arterial and coronary sinus 
blood were obtained immediately after the 1-minute 
bradykinin infusion for NO level determination. 
After return of CBF to a steady baseline level (approx- 
imately 30 minutes after bradykinin infusion), endotheli- 
urn-independent relaxation was tested by infusing sodium 
nitroprusside mixed in blood to a final concentration of
10 -6  mol/L in the same manner as that of bradykinin, and 
the average CBF per minute was expressed as percent 
increase of baseline CBF before nitroprusside infusion. 
The hearts were then arrested with either the modified 
low-potassium UWS (group 1, n = 8, K + = 25 mEq/L) or 
the standard high-potassium UWS (group 2, n = 8, K + = 
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Fig. 1. Diagram of isolated nonworking perfusion circuit. BCD, Blood cardioplegia device; A, artery; V, 
vein; Ao, aorta; RA, right atrium; LA, left atrium; PA, pulmonary artery; RV, right ventricle; LV,, left 
ventricle. 
129 mEq/L) delivered at 50 mm Hg until arrest and then 
at 40 mm Hg for a period of 2 minutes while topical 
cooling was provided with iced saline slush. Two-minute 
doses of cold cardioplegic solution were given at 40 mm 
Hg every 20 minutes. After 2 hours of arrest, the hearts 
were reperfused with warm (37 ° C) unmodified blood at a 
constant mean pressure of 40 mm Hg, which was raised to 
60 mm Hg after the onset of sinus rhythm. After stabili- 
zation of baseline CBF (approximately i hour after reper- 
fusion), the prearrest experimental protocol with bradyki- 
nin and nitroprusside infusion was repeated. NO samples 
were obtained after the bradykinin infusion. 
NO analysis. After collection, whole-blood samples 
were immediately placed on ice and then centrifuged at 
4°C for 10 minutes at 3200 rpm. The supernatant was 
obtained and kept at 4 ° C. Aliquots of 100/zl were then 
injected into the measuring apparatus and any nitrite or 
nitrate was rapidly reduced to NO by vanadium at 
98 ° C.19, 24 Oxygen-free purified nitrogen was delivered 
into a reaction flask and was drawn into the Dasibi 
Chemiluminescence NOx Analyzer (model 2108, Dasibi, 
Glendale, Calif.) at a constant rate of 200 ml/min with the 
aid of a vacuum pump. The detector is sensitive to the 
nitrogen dioxide radical, the photon-emitting product 
generated by the reaction between ozone and NO. The 
analyzer was calibrated before each use with a standard 
mixture of 825 ppm NO in oxygen-free nitrogen (Scott- 
Martin, Inc., Riverside, Calif.). Results were expressed in 
nanomoles per 100/xl. The arteriovenous difference was 
then calculated and multiplied by the CBF to obtain the 
release rate of NO in nanomoles per minute. 
Statistical analysis. A two-tailed, paired t test was used 
to compare the percentage increase in CBF from the 
baseline value before and after arrest and to compare the 
release of NO before and after preservation. Ap  value of 
less than 0.05 was considered to be statistically significant. 
Animal care. All animals were cared for in compliance 
with the "Principles of Laboratory Animal Care" formu- 
lated by the National Society for Medical Research and 
the "Guide for the Care and Use of Laboratory Animals" 
prepared by the National Academy of Sciences and pub- 
lished by the National Institutes of Health (NIH Publica- 
tion No. 86-23, revised 1985). 
Results 
Endothelium-dependent vasodilation. The per- 
centage increase of CBF in response to bradykinin 
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Fig. 2. Endothelium-dependent vasodilation after brady- 
kinin infusion. 
was significant in both groups before arrest: 237% + 
14.0% of baseline in group 1 (n = 8, 15 + 1.81 
versus 35.02 + 4.13 ml/min, p = 0.001) and 231% _+ 
13.7% of baseline in group 2 (n = 8, 14.89 + 1.03 
versus 31.94 _+ 3.47 ml/min, p = 0.001). There was 
no significant difference in vasodilatory response 
between the two groups (p = 0.58). After 2 hours of 
multidose cardioplegic arrest, the percent increase 
of CBF in response to bradykinin was maintained in 
group 1, in contrast o the result in group 2: the 
percent increase was 232% + 16.0% of baseline in 
group 1 (n = 8, 22.88 _+ 1.72 versus 53.06 _+ 5.14 
ml/min) but only 163% _+ 12.8% of baseline in 
group 2 (n = 8, 24.5 _+ 1.66 versus 36.38 + 1.74 
ml/min; Fig. 2). There was no significant difference 
between prearrest and postarrest responsiveness in 
group 1 (p = 0.59); however, the vasodilatory e- 
sponse to bradykinin was significantly decreased 
after arrest compared with the prearrest response in 
group 2 (p = 0.002) (Fig. 2). 
NO release. The mean NO release after stimula- 
tion with bradykinin revealed no significant differ- 
ence between prearrest (8.63 + 2.91 nmol/min per 
gram) and postarrest values (8.06 _+ 2.51 nmol/min 
per gram; p = 0.88) in group 1 (Fig. 3). In contrast, 
there was a significant decrease in NO release in the 
hearts preserved in high-potassium UWS (group 2) 
after arrest compared with the prearrest level (pre- 
arrest 8.25 + 2.3 versus postarrest -2.46 _+ 2.29 
nmol/min per gram, p = 0.005; Fig. 3). 
Endothelium-independent vasodilation. Before 
cardioplegic arrest, a significant increase of CBF was 
observed in both groups: 194% + 7.5% of baseline 
value in group 1 (14.63 + 1.87 versus 27.96 + 3.20 
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Fig. 3. NO release after bradykinin infusion. 
ml/min, p = 0.001) and 209% _+ 13% of baseline value 
in group 2 (14.06 + 1.30 versus 30.19 + 4.20 ml/min, 
p = 0.001) (Fig. 4). After 2 hours of arrest, the 
response to nitroprusside r mained unchanged inboth 
groups: 187% _+ 10% of baseline value in group 1 
(20.0 _+ 2.49 versus 36.88 _+ 3.86 ml/min, p = 0.001) 
and 194% _+ 17% of baseline value in group 2 (16.75 
_+ 2.27 versus 30.27 _+ 2.36 ml/min, p = 0.001) (Fig. 4). 
Endothelium-independent vasodilatory esponse to ni- 
troprusside revealed no significant difference between 
groups before and after arrest (p = 0.33 for group 1 
andp = 0.75 for group 2; Fig. 4). 
Discussion 
Our previous investigations have revealed that 
multidose UWS containing 129 mmol/L of potas- 
sium is detrimental to endothelial function, 24 al- 
though UWS is generally known to be clinically and 
experimentally successful in extended solid organ 
preservation (kidney, liver, pancreas). 24 Studies 
from numerous laboratories have demonstrated su- 
perior functional recovery and ischemic periods of 
up to 24 hours with the use of UWS. 7' s UWS is a 
formula designed for the induction and safe main- 
tenance of organ preservation for transplantation. 
Its components are designed to minimize the harm- 
ful effects of hypothermic schemia nd subsequent 
reperfusion. Osmotically active impermeants, that 
is, lactobionate, raft]nose, and pentastarch, have been 
incorporated to improve myocardial recovery by re- 
ducing edema during hypothermic arrest. Other com- 
ponents include allopurinol to reduce oxygen free 
radical production, glutathione to act as an antioxi- 
dant, and adenosine to supply the cell with adenosine 
triphosphate substrates during reperfusion. 25
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Nevertheless, the high potassium concentration of
UWS has been implicated in endothelial cell dam- 
age, causing vasospasm and increased capillary per- 
meability. 26 Sellke and colleagues 27have shown that 
the higher concentration of potassium predisposes 
the myocardial cell to the influx of calcium, thereby 
increasing wall tension. As the concentration of 
potassium increases from 30 to 40 mmol/L, the resting 
membrane potential partially depolarizes, the calcium 
channel is activated, and influx increases, which results 
in an energy-consuming semisystolic arrest. Further- 
more, the low sodium concentration of UWS (30 
retool/L) may exacerbate he calcium influx, especially 
during reperfusion. 27Mankad, Chester, and Yacoub 13 
reported that rat hearts perfused with cardioplegic 
solution containing a potassium concentration of 30 
mEq/L or greater showed decreased endothelial re- 
sponse to vasodilators. Saldanha and Hearse 14 re- 
ported endothelial dysfunction in response to 5-hy- 
droxytryptamine in the rat heart after a 30-minute 
continuous infusion of 20 ° C cardioplegic solution con- 
taining 25 mmol/L of potassium. He and associates, 27a 
however, eported that endothelium ofporcine picar- 
dial coronary arteries is relatively tolerant to hyperkal- 
emia-induced injury at a potassium concentration of
50 mmol/L. In contrast, our low-potassinm group (25 
mmol/L) demonstrated that bradykinin-induced ndo- 
thelium-dependent vasodilatory function is main- 
tained. 
The foregoing discrepancy in the literature sug- 
gests that other factors, including oxygen level, 
ischemia or reperfusion, composition and tempera- 
ture of preservants and reperfusates, and reperfu- 
sion pressure, may lso influence endothelial func- 
tion. Ischemia alone can cause endothelial damage, 
perhaps mediated by oxygen-derived free radicals, 
resulting in the impairment of endothelium-depen- 
dent vasorelaxation caused by EDRF/NO ago- 
nists.2S, 29 Reperfusion with unmodified blood im- 
pairs endothelial function i  coronary arteries 
subjected to normothermic global ischemia. 3° Qui, 
Manche, and Hearse 31 demonstrated that, after 
both ischemia nd reperfusion with a low-potassium 
solution (16 retool/L), endothelium-mediated vaso- 
dilation was attenuated by 50%. Endothelial gener- 
ation of superoxide radicals may be a trigger mech- 
anism for endothelial dysfunction, which is then 
amplified by neutrophil adherence and migration 
into the ischemic region. 32 
Several investigators have examined the effect of 
temperature on endothelial function. Amrani and 
colleagues 33demonstrated that moderate hypother- 
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Fig. 4. Endothelium-independent vasodilation after i- 
troprusside infusion. 
mia (20 ° C) and extremely hyperkalemic UWS for 
cardioplegia (130 mmol/L) induces a marked in- 
crease in coronary vascular esistance that is associ- 
ated with impaired myocardial protection and the 
endothelial function is better preserved at 4 ° C than 
at 20 ° C. 34 Aoki, Kawata, and Mayer 3s reported 
excessive cold cardioplegic solution (lower than 
4 ° C) may cause endothelial dysfunction. Mankad, 
Slavik, and Yacoub 36 have shown that the optimal 
temperature to preserve ndothelial function after 
preservation with UWS is at or below 10 ° C. Our 
cardioplegic temperature was maintained at 4 ° C; 
this may have contributed to the preservation of 
endothelial function in the low-potassium group. 
Evora, Pearson, and Schaff 37 have recently shown 
that hyperkalemic (45 mmol/L) crystalloid cardio- 
plegia does not impair endothelial function in iso- 
lated canine epicardial coronary arteries subjected 
to 45 minutes of arrest. They concluded that endo- 
thelial damage may be induced by other mecha- 
nisms, including high shear stress from large deliv- 
ery volumes and high infusion pressure. 37 There is a 
possibility that high shear stress and pressure to the 
coronary endothelium during reperfusion impair 
endothelial function by mechanical dislodgment of 
weakened endothelial attachments. Sawatari and 
colleagues 38showed that high initial perfusion pres- 
sure (60 mm Hg) reduced coronary vasodilatory 
response to acetylcholine stimulation. In the present 
study, reperfusion was initiated at 40 mm Hg and 
then gradually increased to a mean of 60 mm Hg 
after resumption of cardiac rhythm. 38 However, it is 
still unclear whether a pressure of 40 mm Hg is low 
enough to avoid endothelial damage. Further stud- 
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ies are necessary todetermine the effects of pressure 
and flow on the endothelium. 
Punctuating the variability noted in the literature 
concerning the multitude of factors that affect en- 
dothelial function is our previous report, 24 which, 
although corroborating our current findings of en- 
dothelial dysfunction with use of conventional 
UWS, differs in one regard. Whereas our prior study 
revealed concordant elimination of endothelial re- 
sponse to bradykinin and NO production, our 
present study noted that the endothelial response 
was reduced but not eliminated in the setting of 
absent NO production. It is not clear how these 
apparent contrasting results can be explained. As 
discussed in the foregoing paragraphs, many factors 
influence ndothelial function, and some of these 
factors may have played a hand in our conflicting 
results. Further study is ongoing to examine the 
effects of these factors. Nevertheless, it is clear from 
our studies that endothelial function is adversely 
affected by higher potassium concentrations i  crys- 
talloid cardioplegic solution. 
It is interesting to note in addition that, al- 
though we found an ongoing but diminished 
endothelial response to bradykinin stimulation, 
NO production ceased by our current methods 
of measurement. Two possibilities exist to ac- 
count for this discordance. First, bradykinin has 
known mechanisms of vasodilation that, although 
endothelium dependent, are independent of NO 
production. One such mechanism is bradykinin- 
induced generation of prostacyclin, a known 
vasodilator. 39The prostacyclin pathway may have 
a differential sensitivity to the effects of potassium 
cardioplegia than NO. A second and alternative 
explanation is that current methods for measure- 
ment of NO may not be sufficiently sensitive to 
detect he small amounts of NO release capable of 
inducing vasodilation. It is likely that both these 
factors are operative in our present study. 
It is now apparent hat the vascular endothe- 
lium is an active organ producing at least several 
substances that regulate vascular tone. Furchgott 
and Zawadzki 4° found a potent endothelium- 
derived vasodilator that has been subsequently 
named EDRF. Extensive evidence exists that 
EDRF is NO itself. However, there are several 
important differences between these compounds, 
specifically their chemical characteristics, half- 
lives, sensitivities, and sites of action. 19' 41, 42 The 
principal biochemical mechanism of action of 
EDRF/NO has been elucidated. Subsequent to its 
release, NO, a highly reactive simple gas gener- 
ated from the vascular endothelium, penetrates 
adjacent smooth muscle cell membranes and 
binds to the heme portion of guanylate cyclase. 
Activated guanosine cyclase increases the intra- 
cellular cyclic guanosine monophosphate l vel, 
which in turn reduces the intracellular calcium 
concentration. 43 Sellke and associates 44showed 
that bradykinin induces endothelium-dependent 
relaxation, which is mediated by EDRF, by dem- 
onstrating that selective removal of coronary en- 
dothelium or depletion of vascular smooth muscle 
cyclic guanosine monophosphate markedly re- 
duces the relaxation response to bradykinin stim- 
ulation in porcine microvessels. Linz, Martorana, 
and Schlekens 45reported that bradykinin in con- 
centrations as low as 10 -9 mmol/L increases CBF 
in a concentration-dependent manner in isolated 
working perfused hearts with regional myocardial 
ischemia. We used a bradykinin concentration 
of 10 -6 mmol/L, which resulted in an increase 
in CBF by greater than 230% before arrest. 
This responsiveness was maintained after preser- 
vation with a potassium concentration of 25 
mmol/L, but not in high-potassium UWS. This 
loss of endothelium-dependent r laxation corre- 
lated with decreased NO release. Hence it ap- 
pears that endothelial dysfunction is secondary to 
a high potassium concentration. 
Optimal myocardial preservation remains a major 
concern in heart ransplantation. Fullerton and asso- 
ciates 46 demonstrated coronary vasomotor dysfunction 
and histologic evidence of coronary vascular damage 
acutely after cardiac autotransplantation, which may 
compromise myocardial function. Furthermore, in the 
long term, this could contribute to he development of 
graft coronary artery disease. 46 Our previously pub- 
lished data showed a significantly lower prevalence of 
cardiac allograft vasculopathy in hearts preserved with 
Stanford solution compared with hearts in the UWS 
group at 24 months of mean follow-up. 47 Other inves- 
tigators have correlated endothelial dysfunction with 
graft atherosclerosis. 4& 49 This might be important in 
the progression of accelerated graft atherosclerosis in 
human heart ransplantation. Further investigation is
being done to evaluate the long-term effects of endo- 
thelial dysfunction, i duced by high-potassium UWS, 
on the development of accelerated graft coronary 
artery disease. 
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